Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 6/20 | 0.34 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805539 | 1.00 | FSCN1 (0.37) | FSCN1MAOBMAPK14PTGDR2PPARG | |
| SCHEMBL4807252 | 0.90 | MAPK14 (0.38) | FSCN1MAPK14PPARGALKBH1 | |
| SCHEMBL13986826 | 0.90 | MAPK14 (0.38) | FSCN1MAPK14PPARGALKBH1 | |
| SCHEMBL4807264 | 0.90 | MAPK14 (0.38) | FSCN1MAPK14PPARGALKBH1 | |
| SCHEMBL2945342 | 0.80 | PTGER1 (0.42) | FSCN1PTGDR2PPARGALKBH1PTGER1 | |
| SCHEMBL6222497 | 0.79 | ALKBH1 (0.37) | FSCN1MAPK14PTGDR2ALKBH1PTGER1 | |
| SCHEMBL2943243 | 0.78 | ALDH1A1 (0.40) | FSCN1PTGDR2ALKBH1PTGER1NPC1 | |
| SCHEMBL4809179 | 0.78 | MAPK14 (0.39) | FSCN1MAPK14GRIN2B | |
| SCHEMBL1684271 | 0.78 | FSCN1 (0.37) | FSCN1MAOBMAPK14PTGDR2PPARG | |
| SCHEMBL2943244 | 0.78 | FSCN1 (0.40) | FSCN1MAPK14PTGDR2PPARGALKBH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | FSCN1 4841/4885MAOB 979/4885MAPK14 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.